|
|
|
|
Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer
|
|
|
|
|
|
|
|
نویسنده
|
jiang l. ,huang j. ,higgs b.w. ,hu z. ,xiao z. ,yao x. ,conley s. ,zhong h. ,liu z. ,brohawn p. ,shen d. ,wu s. ,ge x. ,jiang y. ,zhao y. ,lou y. ,morehouse c. ,zhu w. ,sebastian y. ,czapiga m. ,oganesyan v. ,fu h. ,niu y. ,zhang w. ,streicher k. ,tice d. ,zhao h. ,zhu m. ,xu l. ,herbst r. ,su x. ,gu y. ,li s. ,huang l. ,gu j. ,han b. ,jallal b. ,shen h. ,yao y.
|
|
منبع
|
plos genetics - 2016 - دوره : 12 - شماره : 4
|
|
چکیده
|
Small cell lung cancer (sclc) is an aggressive disease with poor survival. a few sequencing studies performed on limited number of samples have revealed potential disease-driving genes in sclc,however,much still remains unknown,particularly in the asian patient population. here we conducted whole exome sequencing (wes) and transcriptomic sequencing of primary tumors from 99 chinese sclc patients. dysregulation of tumor suppressor genes tp53 and rb1 was observed in 82% and 62% of sclc patients,respectively,and more than half of the sclc patients (62%) harbored tp53 and rb1 mutation and/or copy number loss. additionally,serine/arginine splicing factor 1 (srsf1) dna copy number gain and mrna over-expression was strongly associated with poor survival using both discovery and validation patient cohorts. functional studies in vitro and in vivo demonstrate that srsf1 is important for tumorigenicity of sclc and may play a key role in dna repair and chemo-sensitivity. these results strongly support srsf1 as a prognostic biomarker in sclc and provide a rationale for personalized therapy in sclc. © 2016 jiang et al.
|
|
|
|
|
آدرس
|
department of pulmonary,shanghai chest hospital,shanghai jiao tong university,shanghai, China, medimmune,gaithersburg,md, United States, medimmune,gaithersburg,md, United States, department of epidemiology and biostatistics,collaborative innovation center of cancer medicine,jiangsu key lab of cancer biomarkers,prevention and treatment,school of public health,nanjing medical university,nanjing, China, medimmune,gaithersburg,md, United States, medimmune,gaithersburg,md, United States, medimmune,gaithersburg,md, United States, medimmune,gaithersburg,md, United States, medimmune,gaithersburg,md, United States, medimmune,gaithersburg,md, United States, medimmune,gaithersburg,md, United States, medimmune,gaithersburg,md, United States, department of pulmonary,shanghai chest hospital,shanghai jiao tong university,shanghai, China, department of epidemiology and biostatistics,collaborative innovation center of cancer medicine,jiangsu key lab of cancer biomarkers,prevention and treatment,school of public health,nanjing medical university,nanjing, China, department of pulmonary,shanghai chest hospital,shanghai jiao tong university,shanghai, China, department of pulmonary,shanghai chest hospital,shanghai jiao tong university,shanghai, China, medimmune,gaithersburg,md, United States, medimmune,gaithersburg,md, United States, medimmune,gaithersburg,md, United States, medimmune,gaithersburg,md, United States, medimmune,gaithersburg,md, United States, asia & emerging markets imed,astrazeneca r&d,shanghai, China, department of pulmonary,shanghai chest hospital,shanghai jiao tong university,shanghai, China, department of pulmonary,shanghai chest hospital,shanghai jiao tong university,shanghai, China, medimmune,gaithersburg,md, United States, medimmune,gaithersburg,md, United States, department of pulmonary,shanghai chest hospital,shanghai jiao tong university,shanghai, China, department of epidemiology and biostatistics,collaborative innovation center of cancer medicine,jiangsu key lab of cancer biomarkers,prevention and treatment,school of public health,nanjing medical university,nanjing, China, department of epidemiology and biostatistics,collaborative innovation center of cancer medicine,jiangsu key lab of cancer biomarkers,prevention and treatment,school of public health,nanjing medical university,nanjing, China, medimmune,gaithersburg,md, United States, asia & emerging markets imed,astrazeneca r&d,shanghai, China, asia & emerging markets imed,astrazeneca r&d,shanghai, China, beijing genomics institute,shenzhen,guangdong, China, beijing genomics institute,shenzhen,guangdong, China, shanghai cancer institute,renji hospital,shanghai jiaotong university school of medicine,shanghai, China, department of pulmonary,shanghai chest hospital,shanghai jiao tong university,shanghai, China, medimmune,gaithersburg,md, United States, department of epidemiology and biostatistics,collaborative innovation center of cancer medicine,jiangsu key lab of cancer biomarkers,prevention and treatment,school of public health,nanjing medical university,nanjing, China, medimmune,gaithersburg,md, United States
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|